Home
Companies
ReleviumBio

ReleviumBio

Y Combinator LogoS22ActiveDrug discoveryHealthcareTherapeuticsMedical DevicesBiotech

Platform injectable gel based biotherapeutic for osteoarthritis

ReleviumBio is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease. Right now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. To date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. My co-founder and I are Chemists with PhDs in Biomedical Engineering and we have an experienced leadership team already in place. Insurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity. This platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.

Company Launches

ReleviumBio - Life changing Innovation

ReleviumBio is developing a platform peptide gel-based therapy for Osteoarthritis
Read Launch ›

🚀🚀 ReleviumBio: The life-changing biotherapeutic platform for osteoarthritis

Platform peptide gel-based therapy for osteoarthritis
Read Launch ›
ReleviumBio
Founded:2019
Team Size:4
Location:Galway, Ireland

Active Founders

Alison Liddy

Alison is CEO and Co-Founder at Relevium. Alison holds qualifications in Chemistry and Biochemical Engineering (M.Sc. & Ph.D.). She has worked for major multinational companies including ROCHE, Cook Medical and Boston Scientific; and completed the BioInnovate Fellowship in the prestigious Stanford BioDesign-affiliated program at NUI Galway, Ireland. She is the named inventor on over 20 patent publications and the winner of the Science Foundation of Ireland’s €1 million innovation prize.

Alison Liddy
Alison Liddy
ReleviumBio

Barry McDermott

Barry is the CTO of ReleviumBio - a pharmaceutical company based in Galway, Ireland that are developing innovative new gel based therapeutics for chronic diseases such as osteoarthritis. Barry is uniquely qualified as a Pharmacist (Trinity College Dublin) and Veterinarian (University College Dublin), and also holds a PhD in Biomedical Engineering (University of Galway). This cross-disciplinary skillset enables development of effective solutions to urgent clinical needs.

Barry McDermott
Barry McDermott
ReleviumBio